The ML brief report on the conference mentions 13 new drugs by 2002. Initially, I could only come up with 12 candidates:
We have 5 partnered drugs (Allegra, Claritin, Hismanal, Propulsid, Prozac).
Then I would assume Xopenex, formoterol, cetirizine, oxybutinin, sibutramine, ketoprofen and doxazosin (Cardura).
I found the missing one on the slides at the SEPR web site (under presentations). It's an ICE for Effexor, a major anti-depressant. Don't recall seeing this discussed before (although it's getting hard for us biotech-types used to 1- or 2-drug companies to keep track of all these drugs <G>), and it's on a very aggressive time-line.
BTW, the slides say 13 NDA's by 2002, which seems a little more realistic but still very aggressive.
The Claritin II NDA for this year is very good news indeed. SGP must really be hustling.
Peter |
